Data from: Exploratory proteomic analysis implicates the alternative complement cascade in Primary CNS Vasculitis
Data files
Jul 24, 2019 version files 5.50 MB
-
Supplemental_Figure_e2.pdf
162.95 KB
-
SupplementalFig_e1_ExplRev.pdf
4.71 MB
-
Supplementary_Appendix_e1.docx
25.99 KB
-
Supplementary_Appendix_e2_Exploratory_Rev_Neurology.xlsx
516.55 KB
-
Supplementary_Appendix_e3_Exploratory_Rev_Neurology.csv
76.14 KB
Abstract
Objective: To identify molecular correlates of primary angiitis of the central nervous system (PACNS) through proteomic analysis of cerebrospinal fluid (CSF) from a biopsy-proven patient cohort.
Methods: Using mass spectrometry, the CSF proteome of biopsy-proven PACNS patients (n=8) was quantitatively compared to CSF from individuals with non-inflammatory conditions (n=11). Significantly enriched molecular pathways were identified using a gene ontology workflow, and high confidence hits within enriched pathways (fold change >1.5 and concordant Benjamini-Hochberg-adjusted p-value <0.05 on DeSeq and t-test) were identified as differentially regulated proteins.
Results: Compared to non-inflammatory controls, 283 proteins were differentially expressed in PACNS patient CSF, with significant enrichment of the complement cascade pathway (C4-binding protein, CD55, CD59, properdin, complement C5, complement C8 and complement C9) and neural cell adhesion molecules. A subset of clinically relevant findings was validated by western blot and commercial ELISA.
Conclusions: In this exploratory study we found evidence of deregulation of the alternative complement cascade in CSF from biopsy-proven PACNS as compared to non-inflammatory controls. More specifically, several regulators of the C3 and C5 convertases and components of the terminal cascade were significantly altered. These preliminary findings shed light on a previously unappreciated similarity between PACNS and systemic vasculitides, especially Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis. The therapeutic implications of this common biology, and the diagnostic and/or therapeutic utility of individual proteomic findings warrant validation in larger cohorts.